Executive Team

Chief Executive Officer and founder, Mai-Britt Zocca, Ph.D.

Dr. Zocca has served as our founder and Chief Executive Officer since January 2015. Dr. Zocca was also the founder and Chief Executive Officer of OncoNOx ApS, a pharmaceutical company, from July 2011 until May 2019. Prior to founding the Company, she was the Chief Executive Officer at LevOss ApS, a biotechnology company, from January 2012 until January 2017. Dr. Zocca also led DanDrit Biotech A/S, a biotechnology company, as its Chief Executive Officer from July 2007 until December 2010. Dr. Zocca currently serves on the board of directors for Dansk Biotek, a Danish biotechnology trade organization, and Valo Therapeutics Ltd., a biotechnology company. Dr. Zocca received her M.Sc in Biochemistry as well as Ph.D. in Medicine from the University of Copenhagen and NIH, NCI, MD, US.

Chief Financial Officer, Keith Vendola, M.D., M.B.A. 

Dr. Vendola has more than 20 years of experience in healthcare corporate finance as an executive, adviser, and investment banker working on over 50 financing and strategic transactions. He joins IO Biotech from Rezolute, Inc., where he served as CFO, leading the company through a financial transformation and Nasdaq listing. Prior, he served as chief of staff to the CEO and vice president of competitive strategy at Coherus BioSciences, where he acted as the company's main liaison to Wall Street and held responsibilities spanning execution of multiple financings, corporate partnering, strategy, and oversight of investor relations.  Prior, he served in senior roles at Eiger BioPharmaceuticals and Threshold Pharmaceuticals (now Molecular Templates). Earlier in his career, Keith served as an investment banker within the healthcare groups of Banc of America Securities (now BofA Securities) and Chase (now JPMorgan Chase).  

Dr. Vendola received his M.B.A. in finance from Northwestern's Kellogg School of Management, M.D. from Dartmouth Medical School, and B.A. in psychology from the College of the Holy Cross, where he graduated with honors. He completed an executive education program at Harvard Business School focused on strategic negotiations as well as a research fellowship at the National Institutes of Health, where he was an author on multiple papers.

Chief Medical Officer, Eva Ehrnrooth, M.D., Ph.D.

Board-certified oncologist who most recently served as executive director, the global clinical programme team leader at Boehringer Ingelheim. She held clinical development positions of increasing responsibility at Boehringer Ingelheim between 2010 and 2017. Previously Dr. Ehrnrooth was a medical director at Genmab and has been working as oncologist in the Department of Oncology at National Danish Hospital.

Chief Scientific Officer, Dr. Muhammad Al-Hajj

Muhammad brings 18+ years of experience in Oncology drug discovery. He joined IO Biotech from Autolus Therapeutics, where he was Sr VP of Translational Sciences and played a key role in the progression of their CAR-T pipeline. Prior to that, he spent 12+ years in roles of increasing responsibilities leading R&D and Translational Medicine teams at Novartis (NIBR), GlaxoSmithKline & AstraZeneca contributing to the development of approved medicines. He is an inventor on 20+ patents and applications, and his peer-reviewed work has been cited over 15,000 times. He holds a PhD in Molecular Genetics, and completed post-doctoral training in Cancer/Stem Cells at the University of Michigan Cancer Center.

VP, Corporate Finance, Mikkel Dybkjaer, Ms.Econ.

Mikkel has more than 20 years of financial and strategic experience from pharma/biotech companies (e.g. Lundbeck and Genmab) and management consultancy companies (e.g. Accenture). Involved in multiple high value licensing deals/company acquisitions.

SVP, Regulatory, CMC & Quality, Andre Willis

Andrew has over 35 years of experience with quality, regulatory affairs and pharmaceutical development.

VP, Translational Research, Ayako Wakatsuki Pedersen, PhD

Experienced cancer immunologist (15+ years) with preclinical development of immunotherapeutic drugs in biotechs (8+ years).